acquiring Carmot Therapeutics and partnering with Zealand, and AstraZeneca, partnering with Eccogene, have done. We should also note that while Novo's deal with Septerna involves a $195m upfront ...

The deal is valued at up to $2.2bn, including more than $200m in upfront and near-term payments to Septerna. The partnership centres on the discovery and development of oral therapeutics aimed at ...

Analysts' ratings for Septerna SEPN over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...

Investing.com -- Shares of Septerna, Inc. (Nasdaq:SEPN) surged 60% following the announcement of an exclusive global collaboration and license agreement with Novo Nordisk (NYSE:NVO) to develop ...

Septerna may receive up to $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments. The collaboration targets four GPCR programs, including GLP-1 ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

Shares of Septerna SEPN surged 51% on May 14 after ... Several other companies like Amgen AMGN and Viking Therapeutics are also making rapid progress in the development of GLP-1-based candidates ...

COPENHAGEN, May 14 (Reuters) - Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license agreement with Danish pharma company, Novo Nordisk NVO, for developing and ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...